- Home
- LIEN vs ITOS Comparison
LIEN vs ITOS Comparison
Compare LIEN & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- ITOS
- Stock Information
- Founded
- LIEN 2021
- ITOS 2011
- Country
- LIEN United States
- ITOS United States
- Employees
- LIEN N/A
- ITOS N/A
- Industry
- LIEN
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LIEN
- ITOS Health Care
- Exchange
- LIEN NYSE
- ITOS Nasdaq
- Market Cap
- LIEN 264.8M
- ITOS 270.7M
- IPO Year
- LIEN 2022
- ITOS 2020
- Fundamental
- Price
- LIEN $11.47
- ITOS $7.09
- Analyst Decision
- LIEN
- ITOS Strong Buy
- Analyst Count
- LIEN 0
- ITOS 3
- Target Price
- LIEN N/A
- ITOS $26.00
- AVG Volume (30 Days)
- LIEN 9.4K
- ITOS 374.0K
- Earning Date
- LIEN 05-08-2025
- ITOS 03-05-2025
- Dividend Yield
- LIEN 11.86%
- ITOS N/A
- EPS Growth
- LIEN N/A
- ITOS N/A
- EPS
- LIEN 0.67
- ITOS N/A
- Revenue
- LIEN $12,681,914.00
- ITOS $35,000,000.00
- Revenue This Year
- LIEN $71.81
- ITOS N/A
- Revenue Next Year
- LIEN $113.93
- ITOS $121.70
- P/E Ratio
- LIEN $17.20
- ITOS N/A
- Revenue Growth
- LIEN 22.94
- ITOS 177.89
- 52 Week Low
- LIEN $10.54
- ITOS $6.67
- 52 Week High
- LIEN $13.38
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- ITOS 46.03
- Support Level
- LIEN N/A
- ITOS $6.73
- Resistance Level
- LIEN N/A
- ITOS $7.65
- Average True Range (ATR)
- LIEN 0.00
- ITOS 0.38
- MACD
- LIEN 0.00
- ITOS 0.03
- Stochastic Oscillator
- LIEN 0.00
- ITOS 42.86
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company's investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.